Privia Health (PRVA) Q1 2026 earnings review
Top-Line Acceleration Masks Cash Burn and GAAP Profit Reversal
Privia Health delivered a quarter of strong operational acceleration, driving Revenue up 25.8% YoY to $603.8M and pushing Attributed Lives past 1.6 million. However, the quality of earnings is deteriorating. While management touts a 36.3% jump in Adjusted EBITDA to $36.7M, GAAP Net Income is reversing, dropping 27.4% to $3.1M. This disconnect is fueled by an aggressive $21.9M stock-based compensation bill that ate up nearly 60% of the Adjusted EBITDA. Furthermore, Operating Cash Flow collapsed to -$49.5M. The core business is scaling beautifully, but investors are paying for it heavily through dilution and near-term cash burn.
🐂 Bull Case
Implemented providers accelerated by 13.6% YoY to 5,535. Privia's capital-light, tech-enabled model continues to attract independent physicians who want value-based care upside without full capitation risk.
Adjusted EBITDA Margin (as a percentage of Care Margin) expanded by roughly 300 basis points YoY to 28.5%. The platform's fixed costs are scaling efficiently against rising Practice Collections.
🐻 Bear Case
A 23% YoY spike in stock-based compensation ($21.9M) completely erased the operational leverage on a GAAP basis. If PRVA has to issue this much equity to retain talent, real shareholder returns will be capped.
Net cash used in operating activities doubled YoY to -$49.5M. While Q1 is historically a cash-burn quarter due to bonus payouts, the magnitude threatens management's promise of 80% full-year FCF conversion.
⚖️ Verdict: ⚪
Neutral. The operational metrics (lives, providers, collections) are undeniably strong, but the widening gap between Adjusted EBITDA and GAAP Net Income—paired with heavy Q1 cash burn—raises red flags about earnings quality.
Key Themes
Attributed Lives Growth Accelerating
Attributed Lives jumped 26.5% YoY to 1,606,000, heavily aided by the late-2025 Evolent ACO acquisition. This top-of-funnel metric is accelerating, providing a massive patient base across which Privia can negotiate shared-savings contracts and deploy care management fees. PRVA has already surpassed the low end of its initial FY26 guidance for lives in Q1 alone.
Operating Leverage is Stable and Expanding
Platform Contribution grew 29.6% YoY to $67.0M, drastically outpacing Care Margin growth (22.3%). This proves that as Practice Collections scale, Privia is successfully holding the line on its underlying Cost of Platform. This operating leverage is the primary driver pushing the company toward its long-term 30-35% Adjusted EBITDA margin target.
GAAP to Non-GAAP Disconnect Widening
This is the most critical data point contradicting the positive growth narrative: while Adjusted EBITDA grew 36.3%, GAAP Net Income is reversing, dropping 27.4% YoY. The bridge between the two is $21.9M in stock-based compensation, up from $17.8M a year ago. Management highlights an 'asset-light' model, but heavily compensating providers and executives with stock represents a real, dilutive cost to shareholders.
Severe Operating Cash Burn
Cash flow from operations is reversing violently, dropping from -$24.1M in 25Q1 to -$49.5M in 26Q1. This was driven primarily by a $112.8M balloon in Accounts Receivable and $55.3M in claims paid. While Q1 is seasonally weak for PRVA, a $60M total drop in cash reserves in a single quarter puts heavy pressure on the remaining three quarters to achieve the guided 80% FCF conversion.
Macro Resilience in Medicare Advantage (MA)
As full-risk capitated models across the healthcare sector face margin destruction from MA utilization spikes and V28 coding changes, Privia's shared-risk model remains stable. Management has deliberately avoided full-risk capitation, protecting their downside while maintaining upside potential via the Medicare Shared Savings Program (MSSP).
AI Integration Driving Physician Productivity
To combat physician burnout and streamline fee-for-service workflows, Privia is rolling out Navina and other AI-driven point-of-care decision support tools. This technology integration is a crucial driver for same-store practice collections growth, allowing existing physicians to handle higher volumes with lower administrative overhead.
Capitated Medical Claims Risk Creeping Up
While management states they are avoiding full-risk MA contracts, liabilities for unpaid medical claims under at-risk capitation arrangements grew to $105.2M, up 21.8% from $86.4M a year ago. Incurred health care costs for the current year outpaced capitated revenue growth, requiring strict monitoring in upcoming quarters to ensure underwriting remains sound.
Other KPIs
Accelerating. Up 14.6% YoY, showing consistent, robust volume moving through Privia's billing pipes. This remains the purest indicator of physician productivity and patient volume under the Privia umbrella.
Reversing standard working capital efficiency. A/R spiked dramatically from $400.9M at the end of FY25. This $112M quarter-over-quarter drain on working capital is the primary culprit behind the severe negative operating cash flow. Management needs to demonstrate this is a mere timing issue with payer collections.
Guidance
Accelerating. Management raised the low end of guidance (previously 1,550,000). Given PRVA closed Q1 at 1,606,000 lives, achieving this guidance is highly probable. It represents an implied YoY growth of ~4.6% from the end of FY25, though much of this was front-loaded via the Evolent integration.
Stable. The midpoint of $150M implies a 19.5% YoY growth rate over FY25's $125.5M. The company is tracking perfectly against this target with $36.7M delivered in Q1 (roughly 24% of the full-year target), maintaining their promise of ~20% annual EBITDA compounding.
Stable. The $2.40B midpoint implies a 13.1% YoY growth rate from FY25's $2.12B. With Q1 printing $603.8M (25% of the total target), the company is executing exactly to plan on the top line.
Key Questions
Bridging the Cash Flow Gap
Operating cash flow was -$49.5M this quarter, heavily impacted by a $112M spike in Accounts Receivable. Can you walk us through the timing of these collections and your confidence level in still achieving 80% FCF conversion for the full year?
Stock-Based Compensation Trajectory
SBC grew 23% YoY and now represents nearly 60% of Adjusted EBITDA, driving a GAAP net income decline. Is this $22M run-rate the new normal post-Evolent and IMS integrations, or should we expect this to scale down as a percentage of revenue?
Evolent Cross-Sell Momentum
With the Evolent ACO integration now fully underway, how many of those ~1,000 'lighter model' physicians have entered the pipeline to migrate onto Privia's full tech and medical group platform?
Capitated Medical Claims Spike
Liabilities for unpaid medical claims jumped nearly $20M YoY. Are you seeing specific utilization pressures within that small subset of capitated lives, or is this strictly a function of population volume growth?